
Opinion|Videos|April 16, 2025
Overcoming Inertia in Hypercortisolism Identification
Experts discuss how hypercortisolism affects health care utilization and costs for patients, comparing it with patients with other chronic diseases, and how our understanding of the clinical presentation of hypercortisolism has evolved, distinguishing overt hallmark symptoms from nonspecific features overlapping with chronic disease.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How does hypercortisolism affect health care utilization and costs for patients?
- How does this compare with patients with other chronic diseases?
- How has our understanding of the clinical presentation of hypercortisolism evolved?
- Overt, hallmark symptoms and features vs nonspecific features and symptoms overlapping with chronic disease
Advertisement
Related to this article

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
RAPID: Etripamil Converts Two-Thirds of Recurrent PSVT Episodes After Ablation
3
Metformin May Lower Cardiac Dysfunction Risk During VEGF Inhibitor Therapy
4
Building Trust Into Community Kidney Screening, With David Van Wyck, MD
5

